Half-Year 2022 Financial and Clinical Trials Update
2022: Key late-stage news flow* and upcoming IR events
Regulatory
Phase III/ pivotal
readouts
Compound
Vabysmo
Susvimo
Lunsumio (mosunetuzumab)
Tecentriq
Hemlibra
Polivy + R-CHP
glofitamab
Tecentriq + tiragolumab + chemo
Tecentriq + chemo
Tecentriq + tiragolumab
Tecentriq
giredestrant
Tecentriq + Avastin
Venclexta + dexamethasone
Tecentriq + chemo
Tecentriq + tiragolumab + chemo
Alecensa
gantenerumab
Susvimo
Susvimo
Indication
nAMD/DME
nAMD
3L+ FL
Adjuvant NSCLC
Mild to moderate hemophilia A
1L DLBCL
3L+ DLBCL
1L ES-SCLC
Adjuvant SCCHN
1L PDL1+ NSCLC
Adjuvant RCC
2/3L HR+ MBC
Adjuvant HCC
t(11;14) R/R MM
Neoadjuvant NSCLC
1L esophageal cancer
Adjuvant ALK+ NSCLC
Alzheimer's disease
DME
DR
Milestone
US/EU approval
US
EU approval
2023
US/EU approval
EU
EU approval
EU approval
EU/US approval
Ph lb NP30179
Ph III SKYSCRAPER-02
Ph III IMvoke010
Ph III SKYSCRAPER-01
Ph III IMmotion010
Ph II acelERA
Ph III IMbrave050
Ph III CANOVA
Ph III IMpower030
Ph III SKYSCRAPER-08
Ph III ALINA
Ph III GRADUATE 1/2
Ph III PAGODA
Ph III PAVILION
EU
x
2023
Continues to OS IA
Х
2023
Virtual event
Angiogenesis
Monday, 14 February
16:30 to 17:45 CEST
Virtual event
MDA
Wednesday, 16 March
16:30 to 17:30 CEST
Roche ESG Day
Access to Healthcare
Monday, 16 May
15:00 to 16:30 CEST
Virtual event
ASCO
Roche Pharma Day
Virtual event
London
ASH
Monday, 12 September
TBA
10:00 to 15:00 BST
Monday, 6 June
16:00 to 17:30 CEST
* Outcome studies are event-driven: timelines may change; OS-overall survival; IA=interim analysis
Roche
الله
33View entire presentation